Athletes HeartMARATHONNCT02568072
Training-induced Increased Left Ventricular Trabeculation
An observational study of Athletes Heart and Left Ventricular Hypertrabeculation, run by St George's, University of London at 1 site in United Kingdom.
Trial summary
This project will expand on research conducted by the investigators' group, where the investigators have demonstrated increased LV trabeculation, satisfying currently existing criteria for LV Non-Compaction Cardiomyopathy (LVNC), in groups exposed to high cardiac workloads. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Athletes Heart, Left Ventricular Hypertrabeculation
- How many people
- 120 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Oct 2015to Jul 2016
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Healthy participants running first marathon event in Virgin London Marathon 2016.
Who may be able to join
- 1. Asymptomatic and normotensive sedentary individuals (≤2 hours/week of physical activity) aged 18-35 years
Who cannot join
- Hypertension;
- Previous cardiac history;
- Symptoms suggestive of cardiac disease;
- Use of anabolic steroids;
- Use of performance enhancing drugs;
- Abnormal ECG (As defined by the proposed refined ECG screening criteria for black and white athletes published by the Investigators' group)
Show all 10Show fewer
- Left ventricular hypertrophy >15 mm in males and >12 mm in females;
- Significant valvular heart disease or intra-cardiac shunt on echocardiography
- Individuals with contraindications to cardiac MRI scanning
- Pregnant or breastfeeding women.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Increased Left Ventricular Trabeculation in Athletes - a Marker of Left Ventricular Non-compaction or a Physiological Epiphenomenon of Increased Cardiac Preload?
This project will expand on research conducted by the investigators' group, where the investigators have demonstrated increased LV trabeculation, satisfying currently existing criteria for LV Non-Compaction Cardiomyopathy (LVNC), in groups exposed to high cardiac workloads. To the investigators' knowledge, this will be the first prospective study aiming to demonstrate a direct relationship between high levels of exercise and increased LV trabeculation. This study may add weight to the theory that this entity currently described as LVNC, is a morphological epiphenomenon common to many distinct myocardial remodeling processes associated with increased cardiac preload and afterload and may better define normal adaptive increases in LV trabeculation.
Read the detailed description
Background of Left Ventricular Non-Compaction Cardiomyopathy Left Ventricular Non-Compaction Cardiomyopathy (LVNC) is a myocardial disorder defined by increased left ventricular (LV) trabeculation and intertrabecular recesses communicating with the LV cavity. The condition is associated with progressive heart failure, systemic thromboembolism and a predilection to fatal ventricular arrhythmia and sudden cardiac death. However, a large proportion of affected individuals may be asymptomatic. One cohort study demonstrated 28% of detected cases of LVNC were asymptomatic, with the majority being identified through family screening. It must be emphasized that currently there is no diagnostic tool, neither genetic nor imaging, that can categorically identify an individual as having LVNC or not. This lack of a 'gold standard' makes the description of increased left ventricular trabeculation difficult, creating a tendency to apply a diagnostic label of LVNC inappropriately.
Traditional thought has been that LVNC results from arrest of the normal trabecular regression and myocardial compaction that occurs during embryological development. However, this concept is challenged by reported cases of 'acquired' LVNC, where serial echocardiograms have demonstrated a transition from a normal endocardial appearance to a hypertrabeculated LVNC phenotype. Whether this is a delayed presentation of a genetically heterogeneous cardiomyopathy or a morphological epiphenomenon shared by many phenotypically distinct cardiomyopathies, remains unknown. This irresolution is exemplified by international discordance, with the American Heart Association classifying LVNC as a genetic cardiomyopathy and the European Society of Cardiology and World Health Organisation taking the view that LVNC remains an 'unclassified cardiomyopathy'.
In the absence of congenital heart disease, LVNC was thought to be an extremely rare condition with a prevalence between 0.05% and 0.24%. Technical advances in echocardiography, largely second harmonic imaging, have led to improvement in LV apex and lateral wall visualization, which has dramatically increased the frequency of detection in the last 20 years.
Limitations in current diagnostic criteria At present, various diagnostic criteria exist entirely based on morphological findings on echocardiography or magnetic resonance imaging (MRI). All of these criteria have limitations in that they are generated from small patient cohorts, have substantial inter-observer variability and poor correlation between them. This is perhaps not surprising as they all measure different parameters in different echo planes and during different phases of the cardiac cycle.
In a study by Kohli et al, 24% of heart failure patients had at least one of three diagnostic echocardiography criteria for LVNC (Chin 19%, Jenni 15%, Stollberger 13%), as well as 8% of healthy controls, most of whom were of black ethnicity. Only 7% fulfilled all three criteria, indicating the relatively poor concordance between these criteria. These studies highlight the concern that echocardiographic criteria are too sensitive and lack specificity, particularly in black individuals, resulting in over-diagnosis of LVNC.
Whilst MRI has advantages over echocardiography in tissue characterisation, superior contrast-to-noise and signal-to-noise ratio and greater ability to visualize the cardiac apex, CMR criteria for the identification of LVNC suffer the same limitations as for echocardiography. When applying CMR criteria from Petersen et al, a recent population-based prospective multi-ethnic cohort study identified 25.7% of a low-risk 'healthy' population meeting criteria for LVNC.
Currently, application of imaging-based criteria for diagnosis to low risk populations creates a considerable burden of anxiety, potential loss of opportunity/earnings, unnecessary investigations and clinical follow-up, with their associated costs to the National Health Service. There is a considerable need in this area to evaluate what cardiac imaging criteria contribute to the diagnosis of LVNC. Indeed, some propose integration of clinical criteria including malignant arrhythmias, thromboembolic events, neuromuscular disorders and family history of LVNC into a diagnostic algorithm, though none currently exist.
Influence of ethnicity in cardiac remodeling and pilot data Racial differences in cardiac remodeling have previously been described with respect to cardiac hypertrophy. Athletes develop physiological increases in LV wall thickness and cavity size in an adaptive response to high cardiac preload and afterload. This response is exaggerated in black athletes. For the purposes of this study, black ethnicity will be defined as a person of African or African-Caribbean origin. In a study comparing highly trained male athletes, 18% of black athletes exhibited left ventricular hypertrophy (LVH), as defined as an LV wall thickness of >12mm, compared with only 4% of white athletes (p<0.001)13.
The investigators' group has shown that athletes also display a higher prevalence of increased LV trabeculation compared with controls (18.3% vs 7.0%; p < 0.0001) with 8.1% of athletes fulfilling conventional echocardiographic criteria for LVNC. As with LVH, this difference in LV hypertrabeculation appears to be exaggerated in black athletes as compared to white athletes (28.8% vs 16.3%; p = 0.002).
The investigators' group has also investigated the presence of increased LV trabeculation in a population of sickle cell anaemia patients. Chronic anaemia of sickle cell disease is associated with an increased LV preload and high cardiac output. The investigators found increased LV trabeculation in 28% of sickle cell anaemia patients as compared with 12% of asymptomatic healthy black controls. 8% of sickle cell anaemia patients fulfilled both Chin and Jenni criteria for LVNC.
These studies have limitations in their cross-sectional design and therefore a relationship of temporal causality between increased cardiac preload and the development of increased LV trabeculations could not be established.
This led the investigators' group to conduct a longitudinal cohort study utilizing pregnancy as a model of increasing cardiac preload and observing the effects on LV trabeculation. During pregnancy, at 28-36 weeks gestation, in increase in LV trabeculation was seen in 25.4%, having demonstrated normal myocardium at baseline. Moreover, 7.8% of women fulfilled Chin and Jenni criteria for LVNC. In addition, black women appeared to demonstrate a higher prevalence of increased LV trabeculation as compared with white women (46% vs. 13%; p = 0.0003).
With this proposed study the investigators aim to be the first to demonstrate that LV hypertrabeculation can be induced with athletic training in individuals with structurally normal hearts and that this will return to baseline after de-training. Although the population sampled will be a healthy cohort, the implications of the investigators' findings would resonate throughout the cardiac imaging community and fundamentally change perspective on the clinical detection of increased left ventricular trabeculation. The investigators aim to go further than before and compare echocardiographic and CMR measurements of left ventricular trabeculation and investigate whether a positive correlation exists between improvement in cardiopulmonary performance and extent of de novo LV hypertrabeculation. The project will also enable the assessment of the impact of gender on the development of LV trabeculation.
Should the investigators' hypothesis prove correct, this would potentially avoid inappropriate diagnostic labelling, unnecessary anxiety, investigations, treatment, follow up and family screening. This study may strongly emphasize the need for more robust diagnostic criteria for the diagnosis of LVNC.
- Keywords
- exercise, cardiac remodelling, left ventricular non-compaction cardiomyopathy
- Medical subject headings
- Motor Activity
What is being measured
The primary outcome is the main question the study is designed to answer.
Thickness of Compacted Myocardial Tissue (cm)
Measured on echocardiography and cardiac magnetic resonance:
- Echocardiographic measure of compacted myocardial tissue (systole) - Jenni Compacted layer measurement (cm)
- Cardiac magnetic resonance measure of compacted myocardial tissue (diastole) - Petersen Compacted layer measurement (cm)
Measured: Baseline and 7 months
Thickness of Non-compacted Myocardial Tissue (cm)
Measured on echocardiography and cardiac magnetic resonance:
- Echocardiographic measure of non-compacted myocardial tissue (systole) - Jenni Non-Compacted layer measurement (cm)
- Cardiac magnetic resonance measure of non-compacted myocardial tissue (diastole) - Petersen Non-Compacted layer measurement (cm)
Measured: Baseline and 7 months
Myocardial Fractal Dimension
Measured on cardiac magnetic resonance, dimensionless unit and measure of endomyocardial boarder complexity. The higher the value the greater the endocardial boarder complexity and therefore the more trabeculation.
Two measurements were made:
- Captur et al. Global mean left ventricular fractal dimension
- Captur et al. Maximum apical fractal dimension
These values are between 1 and 2. Binarisation eliminates pixel detail originating from the blood pool. The edge image is covered by a series of grids. The minimum size is set to 2 pixels. The maximum size of the grid series is dictated by the dimensions of the bounding box, referring to the smallest rectangle that encloses the foreground pixels. Through the implementation of this 2D box-counting approach, a fractal output of between 1 and 2 is expected. The log-lot plot (e) produces a good fit using linear regression and yields a gradient equivalent to - FD (1.363).
Measured: Baseline and 7 months
Secondary outcomes (1)
Increase in Peak Oxygen Consumption on Cardiopulmonary Exercise Testing After Training
peak oxygen consumption measured by cardiopulmonary exercise testing on a semi-recumbent cycle ergometer. Reported standardised to age, gender, height and weight in ml/kg/min
Measured: Baseline and 7 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2015 (estimated)
- Study startOct 2015
- Primary completionJul 2016
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Athletes HeartStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- St George's, University of London
- Sponsor type
- University, hospital or other
- Collaborators
- St. Bartholomew's Hospital, Cardiac Risk in the Young, British Heart Foundation
- Responsible party
- Sponsor
- Investigators
- Sanjay Sharma, MD FRCP FESC, Principal investigator, St George's, University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02568072
- Sponsor's protocol ID
- 15.0035
- Other IDs
- FS/15/27/31465
- Acronym
- MARATHON
- Status last verified
- Jul 2021
- First submitted
- 28 Sep 2015
- Last updated
- 5 Aug 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increased Left Ventricular Trabeculation in Athletes - a Marker of Left Ventricular Non-compaction or a Physiological Epiphenomenon of Increased Cardiac Preload?
- ClinicalTrials.gov ID
- NCT02568072
- Acronym / sponsor ID
- MARATHON / 15.0035
- Keywords
- exercise, cardiac remodelling, left ventricular non-compaction cardiomyopathy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- St George's, University of LondonUniversity, hospital or other
- Collaborators
- St. Bartholomew's Hospital, Cardiac Risk in the Young, British Heart Foundation
- Study start
- Oct 2015
- Primary completion
- Jul 2016 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 5 Oct 2015 (estimated)
- Results
- Posted 5 Aug 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project will expand on research conducted by the investigators' group, where the investigators have demonstrated increased LV trabeculation, satisfying currently existing criteria for LV Non-Compaction Cardiomyopathy (LVNC), in groups exposed to high cardiac workloads. To the investigators' knowledge, this will be the first prospective study aiming to demonstrate a direct relationship between high levels of exercise and increased LV trabeculation. This study may add weight to the theory that this entity currently described as LVNC, is a morphological epiphenomenon common to many distinct myocardial remodeling processes associated with increased cardiac preload and afterload and may better define normal adaptive increases in LV trabeculation.
Detailed description
Background of Left Ventricular Non-Compaction Cardiomyopathy Left Ventricular Non-Compaction Cardiomyopathy (LVNC) is a myocardial disorder defined by increased left ventricular (LV) trabeculation and intertrabecular recesses communicating with the LV cavity. The condition is associated with progressive heart failure, systemic thromboembolism and a predilection to fatal ventricular arrhythmia and sudden cardiac death. However, a large proportion of affected individuals may be asymptomatic. One cohort study demonstrated 28% of detected cases of LVNC were asymptomatic, with the majority being identified through family screening. It must be emphasized that currently there is no diagnostic tool, neither genetic nor imaging, that can categorically identify an individual as having LVNC or not. This lack of a 'gold standard' makes the description of increased left ventricular trabeculation difficult, creating a tendency to apply a diagnostic label of LVNC inappropriately.
Traditional thought has been that LVNC results from arrest of the normal trabecular regression and myocardial compaction that occurs during embryological development. However, this concept is challenged by reported cases of 'acquired' LVNC, where serial echocardiograms have demonstrated a transition from a normal endocardial appearance to a hypertrabeculated LVNC phenotype. Whether this is a delayed presentation of a genetically heterogeneous cardiomyopathy or a morphological epiphenomenon shared by many phenotypically distinct cardiomyopathies, remains unknown. This irresolution is exemplified by international discordance, with the American Heart Association classifying LVNC as a genetic cardiomyopathy and the European Society of Cardiology and World Health Organisation taking the view that LVNC remains an 'unclassified cardiomyopathy'.
In the absence of congenital heart disease, LVNC was thought to be an extremely rare condition with a prevalence between 0.05% and 0.24%. Technical advances in echocardiography, largely second harmonic imaging, have led to improvement in LV apex and lateral wall visualization, which has dramatically increased the frequency of detection in the last 20 years.
Limitations in current diagnostic criteria At present, various diagnostic criteria exist entirely based on morphological findings on echocardiography or magnetic resonance imaging (MRI). All of these criteria have limitations in that they are generated from small patient cohorts, have substantial inter-observer variability and poor correlation between them. This is perhaps not surprising as they all measure different parameters in different echo planes and during different phases of the cardiac cycle.
In a study by Kohli et al, 24% of heart failure patients had at least one of three diagnostic echocardiography criteria for LVNC (Chin 19%, Jenni 15%, Stollberger 13%), as well as 8% of healthy controls, most of whom were of black ethnicity. Only 7% fulfilled all three criteria, indicating the relatively poor concordance between these criteria. These studies highlight the concern that echocardiographic criteria are too sensitive and lack specificity, particularly in black individuals, resulting in over-diagnosis of LVNC.
Whilst MRI has advantages over echocardiography in tissue characterisation, superior contrast-to-noise and signal-to-noise ratio and greater ability to visualize the cardiac apex, CMR criteria for the identification of LVNC suffer the same limitations as for echocardiography. When applying CMR criteria from Petersen et al, a recent population-based prospective multi-ethnic cohort study identified 25.7% of a low-risk 'healthy' population meeting criteria for LVNC.
Currently, application of imaging-based criteria for diagnosis to low risk populations creates a considerable burden of anxiety, potential loss of opportunity/earnings, unnecessary investigations and clinical follow-up, with their associated costs to the National Health Service. There is a considerable need in this area to evaluate what cardiac imaging criteria contribute to the diagnosis of LVNC. Indeed, some propose integration of clinical criteria including malignant arrhythmias, thromboembolic events, neuromuscular disorders and family history of LVNC into a diagnostic algorithm, though none currently exist.
Influence of ethnicity in cardiac remodeling and pilot data Racial differences in cardiac remodeling have previously been described with respect to cardiac hypertrophy. Athletes develop physiological increases in LV wall thickness and cavity size in an adaptive response to high cardiac preload and afterload. This response is exaggerated in black athletes. For the purposes of this study, black ethnicity will be defined as a person of African or African-Caribbean origin. In a study comparing highly trained male athletes, 18% of black athletes exhibited left ventricular hypertrophy (LVH), as defined as an LV wall thickness of >12mm, compared with only 4% of white athletes (p<0.001)13.
The investigators' group has shown that athletes also display a higher prevalence of increased LV trabeculation compared with controls (18.3% vs 7.0%; p < 0.0001) with 8.1% of athletes fulfilling conventional echocardiographic criteria for LVNC. As with LVH, this difference in LV hypertrabeculation appears to be exaggerated in black athletes as compared to white athletes (28.8% vs 16.3%; p = 0.002).
The investigators' group has also investigated the presence of increased LV trabeculation in a population of sickle cell anaemia patients. Chronic anaemia of sickle cell disease is associated with an increased LV preload and high cardiac output. The investigators found increased LV trabeculation in 28% of sickle cell anaemia patients as compared with 12% of asymptomatic healthy black controls. 8% of sickle cell anaemia patients fulfilled both Chin and Jenni criteria for LVNC.
These studies have limitations in their cross-sectional design and therefore a relationship of temporal causality between increased cardiac preload and the development of increased LV trabeculations could not be established.
This led the investigators' group to conduct a longitudinal cohort study utilizing pregnancy as a model of increasing cardiac preload and observing the effects on LV trabeculation. During pregnancy, at 28-36 weeks gestation, in increase in LV trabeculation was seen in 25.4%, having demonstrated normal myocardium at baseline. Moreover, 7.8% of women fulfilled Chin and Jenni criteria for LVNC. In addition, black women appeared to demonstrate a higher prevalence of increased LV trabeculation as compared with white women (46% vs. 13%; p = 0.0003).
With this proposed study the investigators aim to be the first to demonstrate that LV hypertrabeculation can be induced with athletic training in individuals with structurally normal hearts and that this will return to baseline after de-training. Although the population sampled will be a healthy cohort, the implications of the investigators' findings would resonate throughout the cardiac imaging community and fundamentally change perspective on the clinical detection of increased left ventricular trabeculation. The investigators aim to go further than before and compare echocardiographic and CMR measurements of left ventricular trabeculation and investigate whether a positive correlation exists between improvement in cardiopulmonary performance and extent of de novo LV hypertrabeculation. The project will also enable the assessment of the impact of gender on the development of LV trabeculation.
Should the investigators' hypothesis prove correct, this would potentially avoid inappropriate diagnostic labelling, unnecessary anxiety, investigations, treatment, follow up and family screening. This study may strongly emphasize the need for more robust diagnostic criteria for the diagnosis of LVNC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy participants running first marathon event in Virgin London Marathon 2016.
Key inclusion criteria (1 listed)
- 1. Asymptomatic and normotensive sedentary individuals (≤2 hours/week of physical activity) aged 18-35 years
Key exclusion criteria (10 listed)
- Hypertension;
- Previous cardiac history;
- Symptoms suggestive of cardiac disease;
- Use of anabolic steroids;
- Use of performance enhancing drugs;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Thickness of Compacted Myocardial Tissue (cm)
Time frame: Baseline and 7 months
Measured on echocardiography and cardiac magnetic resonance: 1. Echocardiographic measure of compacted myocardial tissue (systole) - Jenni Compacted layer measurement (cm) 2. Cardiac magnetic resonance measure of compacted myocardial tissue (diastole) - Petersen Compacted layer measurement (cm)
Thickness of Non-compacted Myocardial Tissue (cm)
Time frame: Baseline and 7 months
Measured on echocardiography and cardiac magnetic resonance: 1. Echocardiographic measure of non-compacted myocardial tissue (systole) - Jenni Non-Compacted layer measurement (cm) 2. Cardiac magnetic resonance measure of non-compacted myocardial tissue (diastole) - Petersen Non-Compacted layer measurement (cm)
Myocardial Fractal Dimension
Time frame: Baseline and 7 months
Measured on cardiac magnetic resonance, dimensionless unit and measure of endomyocardial boarder complexity. The higher the value the greater the endocardial boarder complexity and therefore the more trabeculation. Two measurements were made: 1. Captur et al. Global mean left ventricular fractal dimension 2. Captur et al. Maximum apical fractal dimension These values are between 1 and 2. Binarisation eliminates pixel detail originating from the blood pool. The edge image is covered by a series of grids. The minimum size is set to 2 pixels. The maximum size of the grid series is dictated by the dimensions of the bounding box, referring to the smallest rectangle that encloses the foreground pixels. Through the implementation of this 2D box-counting approach, a fractal output of between 1 and 2 is expected. The log-lot plot (e) produces a good fit using linear regression and yields a gradient equivalent to - FD (1.363).
1 secondary outcome
Increase in Peak Oxygen Consumption on Cardiopulmonary Exercise Testing After Training
Time frame: Baseline and 7 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Participant information websiteLink provided by the sponsor.
Related trials for Athletes Heart
RecruitingObservational study
Interaction Between Intraventricular Flow and Cardiac Mechanics Using 3D Echocardiography in Athletes and Sedentary Subjects
Athlete Heart
Not yet recruitingObservational study
Using Heart Electrical Signals to Study How Well Treatments Prevent Dangerous Heart Rhythms in Active People
Inherited Cardiac Conditions, Sudden Cardiac Arrest
Active, not recruitingObservational study
Role of CMR-FT in Assessment of HCM and Athlete's Heart.
Hypertrophic Cardiomyopathies, Athlete Heart
RecruitingObservational study
Prospective Athlete's Heart Study
Athlete Heart
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sanjay Sharma, MD FRCP FESC principal investigator
St George's, University of London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Athletes Heart and Left Ventricular Hypertrabeculation, run by St George's, University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Aug 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thickness of Compacted Myocardial Tissue (cm) (time frame: Baseline and 7 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2021; AzTrials last refreshed its copy on 27 Oct 2026.